Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard
chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.